A CTL-based liposomal vaccine capable of inducing protection against heterosubtypic influenza viruses in HLA-A*0201 transgenic mice

Matsui, Masanao; Kohyama, Shunsuke; Suda, Tatsuya; Yokoyama, Shinichi; Mori, Masahito; Kobayashi, Akiharu; Taneichi, Maiko; Uchida, Tetsuya

doi:10.1016/j.bbrc.2009.12.100

Cited by 33 publications

(23 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Heterosubtypic immunity is mediated by serotype cross reactive CTLs specific for conserved internal proteins like the matrix protein [13,27]. Induction of CTL responses in contrast to an antibody response is indispensable for the suppression of initial viral replication in the respiratory epithelium [12] and furthermore can provide partial [28,29] or complete protection of mice from heterosubtypic influenza viruses [30,31]. CTLs induce apoptosis of virus infected cells after recognizing viral peptides bound to major histocompatibility complex (MHC) class I molecules and secrete antiviral cytokines, notably interferon γ and tumor necrosis factor [32].…”

Section: Discussionmentioning

confidence: 99%

Cytotoxic T cell vaccination with PLGA microspheres interferes with influenza A virus replication in the lung and suppresses the infectious disease

Herrmann

Hartmayer

Planz

et al. 2015

Journal of Controlled Release

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Cytotoxic T cell vaccination with PLGA microspheres interferes with influenza A virus replication in the lung and suppresses the infectious disease

Herrmann

Hartmayer

Planz

et al. 2015

Journal of Controlled Release

View full text Add to dashboard Cite

“…Thereby, liposomes can deliver antigens to the cytosol of APCs (91). Liposomes, containing a short CD8 lipopeptide in combination with CpG, were able to induce protection in a murine influenza challenge model (92). However, liposomes cannot induce maturation of DCs without addition of an adjuvant and are therefore not sufficient to induce co-stimulation.…”

Section: Adjuvants In Peptide Vaccinationmentioning

confidence: 99%

T Cell Responses to Viral Infections â€“ Opportunities for Peptide Vaccination

et al. 2014

View full text Add to dashboard Cite

An effective immune response against viral infections depends on the activation of cytotoxic T cells that can clear infection by killing virus-infected cells. Proper activation of these T cells depends on professional antigen-presenting cells, such as dendritic cells (DCs). In this review, we will discuss the potential of peptide-based vaccines for prevention and treatment of viral diseases. We will describe features of an effective response against both acute and chronic infections, such as an appropriate magnitude, breadth, and quality and discuss requirements for inducing such an effective antiviral immune response. We will address modifications that affect presentation of vaccine components by DCs, including choice of antigen, adjuvants, and formulation. Furthermore, we will describe differences in design between preventive and therapeutic peptide-based vaccines. The ultimate goal in the design of preventive vaccines is to develop a universal vaccine that cross-protects against multiple strains of the virus. For therapeutic vaccines, cross-protection is of less importance, but enhancing existing T cell responses is essential. Although peptide vaccination is successful in inducing responses in human papillomavirus (HPV) infected patients, there are still several challenges such as choosing the right target epitopes, choosing safe adjuvants that improve immunogenicity of these epitopes, and steering the immune response in the desired direction. We will conclude with an overview of the current status of peptide vaccination, hurdles to overcome, and prospects for the future.

show abstract

“…influenza vaccines in recent years, including the use of adjuvants such as CTA1-DD (Cholera toxin subunit A), 12 IL-12, IL-23 13 , poly I:C (TLR3 agonist), [14][15][16] and CS, 17 as well as genetically modified whole viruses. 18 Several delivery systems have been developed to address this issue, including liposomes, [19][20][21][22] nanoparticles, 23 and microspheres 24 ; however, all of these attempts are still at pre-clinical stage maybe due to unsatisfactory immunogenicity, safety concern or complexity in production process. Thus, here we sought to compare the effects of 3 different mucosal adjuvants in i.n.…”

Section: Discussionmentioning

confidence: 99%

Alkyl polyglycoside, a highly promising adjuvant in intranasal split influenza vaccines

Bao

Wang

et al. 2017

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Influenza viral infections are significant global public health concerns due to the morbidity and mortality associated with acute respiratory disease, secondary complications, and pandemic threats; thus, continuous efforts have been made to develop potent influenza vaccines. In this study, 3 different mucosal adjuvants-alkyl polyglycoside (APG), gellan gum, and chitosan (CS)-were evaluated for their efficacy in intranasal A/H1N1 or B split influenza vaccines administered to BALB/c mice. Protective immunity was monitored by serum analysis for IgG, hemagglutination inhibition (HI), and neutralizing antibody levels, as well as mucosal IgA levels in nasal and pulmonary lavage fluids. Survival, body weight, lung viral titer, and pulmonary immunopathology were also examined following lethal influenza challenge. Notably, all adjuvants amplified the IgG and IgA immune responses (not detected in immunization of influenza B) and increased survival rate compared with controls administered adjuvantfree intranasal vaccines. Alternatively, intramuscular immunization stimulated IgG production, but had no effect on IgA levels. Our collective analysis identified that APG was the most effective intranasal adjuvant, as all mice survived influenza challenge with limited body weight loss, viral titer, and pulmonary pathology, similar to those observed with intramuscular vaccination. This evidence supports that APG can elicit both systemic and mucosal immunity, and may be an effective adjuvant in intranasal split influenza A/H1N1 and B vaccines.

show abstract

A CTL-based liposomal vaccine capable of inducing protection against heterosubtypic influenza viruses in HLA-A*0201 transgenic mice

Cited by 33 publications

References 21 publications

Cytotoxic T cell vaccination with PLGA microspheres interferes with influenza A virus replication in the lung and suppresses the infectious disease

Cytotoxic T cell vaccination with PLGA microspheres interferes with influenza A virus replication in the lung and suppresses the infectious disease

T Cell Responses to Viral Infections â€“ Opportunities for Peptide Vaccination

Alkyl polyglycoside, a highly promising adjuvant in intranasal split influenza vaccines

Contact Info

Product

Resources

About